Manesh R. Patel, MD

home / authors / manesh-r-patel-md

Duke University

Articles

Looking Into the Future of Lipid Management

C. Michael Gibson, MD;Payal Kohli, MD, FACC;Manesh R. Patel, MD;Pam Taub, MD, FACC, FASPC

January 11th 2024

Dr Taub, Dr Patel, and Dr Kohli look ahead to the future of the management of cardiovascular risk and hyperlipidemia

How to Select Between Available LDL-C Lowering Therapies

C. Michael Gibson, MD;Payal Kohli, MD, FACC;Manesh R. Patel, MD;Pam Taub, MD, FACC, FASPC

January 11th 2024

Cardiologists discuss how to select the right treatment for your patient with hyperlipidemia

Clinical Trial Results on Novel Nonstatins Agents.

C. Michael Gibson, MD;Payal Kohli, MD, FACC;Manesh R. Patel, MD;Pam Taub, MD, FACC, FASPC

January 11th 2024

Expert cardiologists discuss the recent clinical trials results of the CLEAR-OUTCOMES trial and thee sub analysis on the inflammatory marker hcCRP.

Mechanism of Action of Nonstatin Therapies

C. Michael Gibson, MD;Payal Kohli, MD, FACC;Manesh R. Patel, MD;Pam Taub, MD, FACC, FASPC

January 4th 2024

Dr Kohli gives an overview of the mechanisms of action of non-statin agents for the management of hyperlipidemia.

The Cumulative Burden of LDL-C

C. Michael Gibson, MD;Payal Kohli, MD, FACC;Manesh R. Patel, MD;Pam Taub, MD, FACC, FASPC

January 4th 2024

Expert cardiologists discuss the cumulative burden of an elevated cholesterol over time.

Combination Therapy in LDL Lowering

C. Michael Gibson, MD;Payal Kohli, MD, FACC;Manesh R. Patel, MD;Pam Taub, MD, FACC, FASPC

December 21st 2023

Expert cardiologists describe the importance of combination therapy for hyperlipidemia in high risk patients

Nonstatin Agents for LDL-C Lowering

C. Michael Gibson, MD;Payal Kohli, MD, FACC;Manesh R. Patel, MD;Pam Taub, MD, FACC, FASPC

December 14th 2023

Dr Taub and Dr Patel discuss which non statin agents are available for LDL-C lowering.

How Low is Too Low in LDL-C?

C. Michael Gibson, MD;Payal Kohli, MD, FACC;Manesh R. Patel, MD;Pam Taub, MD, FACC, FASPC

December 14th 2023

Expert cardiologists discuss if there is such a thing as an LDL that is a too low.

Matching the Intensity of Treatment to Cardiovascular Risk

C. Michael Gibson, MD;Manesh R. Patel, MD;Payal Kohli, MD, FACC;Pam Taub, MD, FACC, FASPC

December 7th 2023

Dr Taub discusses how to match the intensity of lipid lowering therapy to the assessed cardiovascular risk.

Assessing Cardiovascular Risk in Your Patients

C. Michael Gibson, MD;Payal Kohli, MD, FACC;Manesh R. Patel, MD;Pam Taub, MD, FACC, FASPC

December 7th 2023

Dr Taub and Dr Patel discuss how to assess for cardiovascular risk in your patients.

Cardiovascular Disease: Future Perspectives

Manesh R. Patel, MD;Marc P. Bonaca, MD, MPH, University of Colorado School of Medicine

June 28th 2021

Marc P. Bonaca, MD, MPH, of the University of Colorado School of Medicine, comments on the potential to personalize treatment with emerging therapies in the pipeline to better manage patients at high risk for cardiovascular disease in the future.

Optimizing Cardiovascular Risk Reduction

Manesh R. Patel, MD;Marc P. Bonaca, MD, MPH, University of Colorado School of Medicine

June 28th 2021

Unmet needs in the management of coronary artery disease and peripheral artery disease, and advice for working with patients and other healthcare professionals to optimize care for patients at high risk for cardiovascular disease.

Individualizing Treatment to Reduce Risks of CVD

Manesh R. Patel, MD;Marc P. Bonaca, MD, MPH, University of Colorado School of Medicine

June 21st 2021

Drs Marc P. Bonaca and Manesh R. Patel discuss the rationale for individualized treatment plans for patients with type 2 diabetes at high risk for cardiovascular disease.

Reducing CV Risk With Dual Antiplatelet/Anticoagulation Therapy

Manesh R. Patel, MD;Marc P. Bonaca, MD, MPH, University of Colorado School of Medicine

June 21st 2021

Implications for treating patients at risk of cardiovascular disease with rivaroxaban plus aspirin based on the COMPASS and VOYAGER PAD clinical trials.

Dual Antiplatelet Therapy for CV Risk Reduction

Manesh R. Patel, MD;Marc P. Bonaca, MD, MPH, University of Colorado School of Medicine

June 14th 2021

Recommendations for treating patients with coronary artery disease and type 2 diabetes with dual antiplatelet therapy based on data revealed by the THEMIS trial.

CV Risk Reduction in Patients with Type 2 Diabetes

Manesh R. Patel, MD;Marc P. Bonaca, MD, MPH, University of Colorado School of Medicine

June 14th 2021

Strategies used to help determine patients’ risk for cardiovascular disease and the role of lifestyle management in helping reduce the risk for events in patients with type 2 diabetes.

Cardiovascular Disease Risk Assessment and Interventions

Manesh R. Patel, MD;Marc P. Bonaca, MD, MPH, University of Colorado School of Medicine

June 7th 2021

Strategies used to help determine patients’ risk for cardiovascular disease and the role of lifestyle management in helping reduce the risk for events in patients with type 2 diabetes.

Risk Factors for Cardiovascular Disease

Manesh R. Patel, MD;Marc P. Bonaca, MD, MPH, University of Colorado School of Medicine

June 7th 2021

Drs Marc P. Bonaca and Manesh R. Patel discuss the link between type 2 diabetes and cardiovascular disease along with risk factors that may lead to cardiovascular events.